Fundraising Fox
A2 Biotherapeutics
Agoura Hills, US · Founded 2017 · Delaware corporation · 5 known investors
Find your way into A2 Biotherapeutics
Sign up to see every warm intro you have to A2 Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the A2 Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.
Founders & leadership
A2 Biotherapeutics was founded in 2017 by C. Alexander Kamb.
Board
Investors · 5
How we know: Nextech Invest's portfolio page · Not right? Tell us
How we know: The Column Group's portfolio page · board seat on SEC Form D · funding news · pharmaceutical-technology.com · the VCSheet dataset · Not right? Tell us
How we know: Vida Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · funding news · pharmaceutical-technology.com · Not right? Tell us
Funding
SEC filings, press & company announcements$223.1M disclosed across 3 of 6 rounds · 2020–2025
- $80MSeries CJan 2025 · 4 sources
Samsara BioCapital, The Column Group
Source ↗ - Undisclosed amountSeries BOct 2020Source ↗
▶$71.6MraisedDec 2022 · 28 investors · BiotechnologyRule 506(b)
- Madhavan BalachandranDirector
- Helen S. KimDirector
- Scott ForakerExecutive Officer, Director
- David LucasExecutive Officer
- Susan L. KelleyDirector
- Srini AkkarajuDirector
- Jakob LovenDirector
- William GoExecutive Officer
- Thomas LeungExecutive Officer
- Alexander KambExecutive Officer, Director
- David GoeddelDirector
- Offering amount
- $71.6M
- Amount sold
- $71.6M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$71.5MraisedOct 2020 · 13 investors · BiotechnologyRule 506(b)
- Scott ForakerExecutive Officer, Director
- Srini AkkarajuDirector
- Madhavan BalachandranDirector
- Michael GalloDirector
- David GoeddelDirector
- C. Alexander KambDirector
- Helen S. KimDirector
- Jakob LovenDirector
- Offering amount
- $71.5M
- Amount sold
- $71.5M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does A2 Biotherapeutics do?
- A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.
- Who founded A2 Biotherapeutics?
- A2 Biotherapeutics was founded by C. Alexander Kamb in 2017.
- Who are A2 Biotherapeutics's investors?
- A2 Biotherapeutics's investors include Mana Ventures, Nextech Invest, The Column Group, Vida Ventures, Samsara BioCapital.
- How much funding has A2 Biotherapeutics raised?
- A2 Biotherapeutics has disclosed $223.1M raised across 3 of its 6 known rounds.
- Where is A2 Biotherapeutics headquartered?
- A2 Biotherapeutics is headquartered in Agoura Hills, US.